The Center for Veterinary Medicine at the FDA has reviewed Loyal’s data, results, and scientific arguments and determined they provide reasonable expectation of the drug’s effectiveness to extend canine lifespan and healthspan. Pending successful completion of the Manufacturing and Safety sections, Loyal will receive conditional approval for LOY-001, allowing them to market the drug for large-dog lifespan extension.